- Lexaria just completed its HYPER-H21-4 human clinical hypertension study, posting a sustained drop in blood pressure in normally active hypertensive patients
- With the success of this study, the company is working towards an IND application to seek FDA approval for its patented DehydraTECH(TM)-enabled CBD capsule formulation.
- 47% of adults live with hypertension but only 24% of them have it under control
- With its DehydraTECH-CBD, Lexaria hopes to not only address the severe unmet patient need associated with hypertension but also tap into a market that is set to be valued at $34 billion by 2030
Lexaria Bioscience (NASDAQ: LEXX), a global leader in enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs, is looking to push the conversation about high blood pressure.
Lexaria continues to move forward, most recently with the success in its latest human clinical study, HYPER-H21-4. The study may be the first to evidence a sustained drop in blood pressure in normally active patients following multiple weeks of oral cannabidiol (“CBD”) therapy using the company’s patented DehydraTECH(TM) technology (https://ibn.fm/cB22n).
Since Lexaria began developing DehydraTECH in 2014, it has continued to strengthen and broaden the technology, exploring various areas including but not limited to the oral administration of antivirals, cannabinoids, vitamins, nicotine, and PDE5 inhibitors. In early 2021, it began dosing in its first human clinical study that assessed its DehydraTECH-enabled CBD capsule formulation. This would lay the groundwork for subsequent studies while also bolstering the company’s growing list of patents, which currently stands at 27, spread across the world, including the use of DehydraTECH-processed CBD for the treatment of heart disease (https://ibn.fm/Nd0Hf).
Lexaria is working toward an Investigational New Drug (“IND”) application filing to seek U.S. Food and Drug Administration (“FDA”) approval. It hopes to build on the success of the studies so far to enhance its understanding of DehydraTECH-CBD for treating cardiovascular and other disease states beyond hypertension.
Since its inception, Lexaria has been committed to addressing severe unmet patient needs. Hypertension has been one of the company’s main focus areas, with 47% of adults living with the condition, but only 24% have it under control. Through its research, it looks to address the condition, ultimately tapping into a market projected to post a CAGR of 3.4% between 2022 and 2030 to hit $34 billion in value (https://ibn.fm/3PBED).
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php